Summary
Ecolab Inc. (ECL) reported strong sales growth of 8% to $12.7 billion for the fiscal year ended December 31, 2021. This performance was driven by double-digit sales growth in the Institutional & Specialty and Other segments, coupled with robust growth in the Industrial segment. Despite facing significant headwinds from cost inflation and supply chain disruptions, Ecolab effectively managed these challenges through pricing increases and volume growth, which more than offset higher delivered product costs. The company also successfully integrated the Purolite acquisition, a significant transaction that closed in December 2021 for $3.7 billion, bolstering its Life Sciences segment. Financially, Ecolab demonstrated solid operational performance, with adjusted operating income increasing by 11% on a fixed currency basis. The company maintained a strong balance sheet, supported by 'A' range credit ratings, and generated robust cash flow from operations of $2.1 billion. Ecolab continues its commitment to returning capital to shareholders, marked by its 30th consecutive annual dividend rate increase. The company is strategically positioned to navigate ongoing economic uncertainties and capitalize on growth opportunities across its diverse end markets.
Financial Highlights
56 data points| Revenue | $12.73B |
| Cost of Revenue | $7.62B |
| Gross Profit | $5.12B |
| R&D Expenses | $186.00M |
| SG&A Expenses | $3.42B |
| Operating Income | $1.60B |
| Interest Expense | $230.60M |
| Net Income | $1.13B |
| EPS (Basic) | $3.95 |
| EPS (Diluted) | $3.91 |
| Shares Outstanding (Basic) | 286.30M |
| Shares Outstanding (Diluted) | 289.10M |
Key Highlights
- 1Reported sales increased 8% to $12.7 billion in 2021, driven by strong performance across key segments.
- 2Acquired Purolite for $3.7 billion, significantly strengthening the Life Sciences segment.
- 3Adjusted operating income (fixed currency) increased by 8% compared to the prior year, reflecting effective cost management and pricing strategies.
- 4Generated $2.1 billion in cash flow from continuing operations, demonstrating strong financial health.
- 5Increased quarterly dividend by 6%, marking the 30th consecutive annual dividend rate increase.
- 6Maintained strong credit ratings (A-/A3/A-) with a commitment to 'A' range metrics.
- 7Successfully navigated supply chain disruptions and cost inflation through pricing and volume management.